Luseogliflozin effective for T2DM with low-carb, high-carb diet

December 29, 2016

(HealthDay)—For patients with type 2 diabetes (T2D), the SGLT2 inhibitor luseogliflozin has similar efficacy when meals contain 40 to 55 percent total energy from carbohydrate (TEC), according to a study published online Dec. 19 in Diabetes, Obesity and Metabolism.

Daisuke Yabe, M.D., Ph.D., from the Kansai Electric Power Research Institute in Kobe, Japan, and colleagues examined the safety and efficacy of luseogliflozin under differing in Japanese individuals with T2D. Participants were randomized to -adjusted meals for 14 days: (HC; 55 percent TEC)-high glycemic index (HGI), HC-low glycemic index (LGI), and low carbohydrate (LC; 40 percent TEC)-HGI. Participants had received luseogliflozin for the past seven days and underwent continuous glucose monitoring (CGM) before and after luseogliflozin treatment.

The researchers found that in all three groups, luseogliflozin significantly decreased the area under the curve and mean CGM values to a similar extent. At all time points, fasting plasma glucose, insulin, and glucagon were similar. On day 15, ketone bodies were significantly increased in LC-HGI versus HC-HGI and HC-LGI.

"In conclusion, luseogliflozin has similar efficacy and safety in Japanese T2D individuals when contain 40 to 55 percent TEC, but a strict low-carbohydrate diet on this class of drug should be avoided to prevent SGLT2 inhibitor-associated diabetic ketoacidosis," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Taisho Toyama, which manufactures luseogliflozin and funded the trial.

Explore further: Fat, carbohydrate quality impact postprandial blood glucose

More information: Full Text (subscription or payment may be required)

Related Stories

Fat, carbohydrate quality impact postprandial blood glucose

February 12, 2016

(HealthDay)—For patients with type 1 diabetes, fat quality influences postprandial blood glucose (PPG) response in the context of meals with high-glycemic index (HGI), according to a study published online Feb. 9 in Diabetes ...

Low-carb diet cuts tx effect of glucagon in hypoglycemia

November 7, 2016

(HealthDay)—For patients with type 1 diabetes, a low-carbohydrate diet (LCD) results in lower incremental rises in plasma glucose (PG) after mild hypoglycemia compared with an isocaloric high-carbohydrate diet (HCD), according ...

Study bodes well for low-carb eaters

November 1, 2016

Three low-carb meals within 24 hours lowers post-meal insulin resistance by more than 30 percent, but high-carb meals sustain insulin resistance, a condition that leads to high blood pressure, prediabetes and diabetes, according ...

Evolocumab safe, effective for those with dysglycemia, MetS

September 16, 2016

(HealthDay)—For patients with or without dysglycemia or metabolic syndrome (MetS), evolocumab is safe and efficacious for reducing low-density lipoprotein cholesterol at 52 weeks, according to research published online ...

Very low carbohydrate diet beneficial for obese with T2DM

August 5, 2014

(HealthDay)—For obese adults with type 2 diabetes mellitus (T2DM), a very low carbohydrate diet is associated with greater improvements in glycemic control and cardiovascular risk markers than an energy-matched high unrefined ...

Recommended for you

Diabetes app forecasts blood sugar levels

April 27, 2017

Columbia University researchers have developed a personalized algorithm that predicts the impact of particular foods on an individual's blood sugar levels. The algorithm has been integrated into an app, Glucoracle, that will ...

New blood test may better predict gestational diabetes

April 27, 2017

A new study led by researchers at Brigham and Women's Hospital has found that a single measurement of plasma glycated CD59 (GCD59), a novel biomarker for diabetes, at weeks 24-28 of gestation identified, with high sensitivity ...

Post-biotics may help shield obese from diabetes

April 20, 2017

You've heard of pre-biotics and pro-biotics, but now you'll be hearing a lot more about post-biotics. Researchers at McMaster University have begun to identify how post-biotics, or the by-products of bacteria, lower blood ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.